Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer

BMC Cancer

Table 2 Clinicopathological and immunohistochemical parameters in relation to RAI-3 immunoreactivity

Variable	Categorisation	RAI-3 immunoreactivity
		n analysable	low^b	abundant^b	p^c
*Clinicopathological data:*
Tumour stage^a
	pT1	46	29	17	0.134
	pT2	74	31	43
	pT3	12	5	7
	pT4	24	13	11
Lymph node status^a
	pN0	68	34	34	0.713
	pN1-3	83	44	39
Histological grade
	G1	16	9	7	0.572
	G2	67	36	31
	G3	72	33	39
Multifocality
	unifocal tumour	130	69	61	0.086
	multifocal tumour	26	9	17
Histological type
	ductal	130	66	64	0.905
	lobular	11	5	6
	other	13	6	7
*Immunohistochemistry (IHC):*
Oestrogen receptor status
	negative (IRS 0–2)	41	23	18	0.557
	positive (IRS 3–12)	89	45	44
Progesterone receptor status
	negative (IRS 0–2)	95	46	49	0.765
	positive (IRS 3–12)	41	21	20
HER2 status
	weak (0–2+)	109	51	58	0.638
	strong (3+)	25	13	12

^aAccording to UICC: TNM Classification of Malignant Tumours. 6^th edn (2002) Sobin LH, Wittekind CH (eds) Wiley: New York
^bRAI-3 immunoreactivity: low = IRS 0–4, abundant = IRS 5–12
^cPearson test (two-sided), bold face representing significant data (P < 0.05)

ISSN: 1471-2407